David M. Berman - 12 Sep 2025 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Role
HEAD OF R&D
Signature
/s/ Lily Hepworth, Attorney-in-Fact
Issuer symbol
IMCR
Transactions as of
12 Sep 2025
Transactions value $
-$413,800
Form type
4
Filing time
16 Sep 2025, 16:15:10 UTC
Previous filing
12 Sep 2025
Next filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Berman David M HEAD OF R&D C/O IMMUNOCORE HOLDINGS PLC, 92 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM /s/ Lily Hepworth, Attorney-in-Fact 16 Sep 2025 0001955244

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMCR Ordinary Shares Options Exercise $393K +22.5K $17.46 22.5K 12 Sep 2025 Direct F1
transaction IMCR Ordinary Shares Sale -$756K -21.2K -94.23% $35.63 1.3K 12 Sep 2025 Direct F1, F2
transaction IMCR Ordinary Shares Sale -$47.2K -1.3K -100% $36.31 0 12 Sep 2025 Direct F1, F3
transaction IMCR Ordinary Shares Options Exercise $3.49K +200 $17.46 200 15 Sep 2025 Direct F1
transaction IMCR Ordinary Shares Sale -$7K -200 -100% $35.01 0 15 Sep 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMCR Employee Share Option (Right to Buy) Options Exercise $0 -22.5K -10.18% $0.00 199K 12 Sep 2025 Ordinary Shares 22.5K $17.46 Direct F1, F5
transaction IMCR Employee Share Option (Right to Buy) Options Exercise $0 -200 -0.1% $0.00 199K 15 Sep 2025 Ordinary Shares 200 $17.46 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $36.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Immediately exercisable.